Atlas Trials

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Clinical trial NCT06762769 · RECRUITING

Trial details

NCT number
NCT06762769
Sponsor
University College, London
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Smouldering Myeloma
Start date
2025-06-02
Primary completion
2032-11-01
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.